drugset
drugset / Trial / NCT04902027

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

NCT04902027 ↗

Phase 1 Completed 45 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with recurrent/metastatic Head and Neck Cancers

Timeline

Start
2021-07-01
Primary completion
2023-10-23
Completion
2023-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous

Indications

head and neck cancer